Oculus Innovative Sciences introduces Microcyn Dermatology HydroGel in the U.S.

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today commercially introduced the Microcyn Dermatology HydroGel for the U.S. professional healthcare market. Oculus announced two weeks ago that it had received FDA 510(k) clearance for the Microcyn Dermatology HydroGel, which under the supervision of a healthcare professional, is intended for management of wounds including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue.

“This is the second U.S. Microcyn product introduction already this year and we’re most excited about bringing the Microcyn Technology to the U.S. dermatology market where we believe this advance in tissue care could potentially have a major impact on the standard of care for multiple skin afflictions”

Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program, has assigned Medicare HCPCS code #A6248 to the Microcyn HydroGel.

“This is the second U.S. Microcyn product introduction already this year and we’re most excited about bringing the Microcyn Technology to the U.S. dermatology market where we believe this advance in tissue care could potentially have a major impact on the standard of care for multiple skin afflictions,” said Hoji Alimi, founder and CEO of Oculus. “At the same time, both our partners as well as our regulatory and marketing teams are busily preparing for six additional FDA regulatory clearances in the U.S. this year alone for multiple indications including oral, allergy and expanded dermatology claims.”